Corrigendum: Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale"

Front Pharmacol. 2016 Dec 5:7:468. doi: 10.3389/fphar.2016.00468. eCollection 2016.

¹ Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples, Italy.
² Department of Onco-Ematology Medical Oncology, S.G. Moscati Hospital of Taranto Taranto, Italy.
³ Unit of Epidemiology, Struttura Complessa di Statistica Medica, Biometria e Bioinformatica, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples, Italy.
⁴ Pharmacy Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples, Italy.
⁵ Division of Urology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples, Italy.
⁶ Scientific Direction, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples, Italy.
⁷ Division of Radiation Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples, Italy.
⁸ Division of Medical Oncology-Centro di Riferimento Oncologico Aviano, Italy.
⁹ Oncology Unit, A.O.R.N. dei COLLI "Ospedali Monaldi-Cotugno-CTO," Naples, Italy.

Abstract

[This corrects the article on p. 287 in vol. 7, PMID: 27630568.].

Keywords: angiogenesis inhibitors; metastatic renal cancer; pazopanib; real world; treatment.